@NStockerSAT
Account based inFrance
About this account
- Account based in
- France
- Connected via
- France App Store
Account-level information from X, not a live location or the device used for a specific post.
MD, PhD | Hematologist at Saint-Antoine Hospital, Paris, France. @HopSaintAntoine @aphp @Sorbonne_Univ_ @crsa_paris
Paris, France
Joined November 2016
- Tweets4.1K
- Following146
- Followers267
- Likes7.4K
Nicolas Stocker retweeted
Chemotherapy with rituximab is now outdated therapy for relapsed DLBCL as combinations including polatuzuamb (like this trial) or bispecific antibodies demonstrate improved survival: Results From the POLARGO Trial | @JCO_ASCO ascopubs.org/doi/full/10.120…
Nicolas Stocker retweeted
Delphi expert consensus on phlebotomy limitations and treatment challenges in HFE-related hemochromatosis | Published in Clinical Hematology International, the official peer-reviewed journal of @TheIACH chi.scholasticahq.com/articl…
Nicolas Stocker retweeted
Impressive results of BrECADD in three days #lymsm
>>> Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma onlinelibrary.wiley.com/doi/…
Nicolas Stocker retweeted
Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Nicolas Stocker retweeted
Excellent efficacy of of acalabrutinib 100 mg twice daily with R-CHOP in treatment-naïve patients with DLBCL , In a phase Ib/II non-randomized study >>> ascopubs.org/doi/full/10.120…
Nicolas Stocker retweeted
High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200…
Nicolas Stocker retweeted
Iron deficiency without anemia: An underrecognized and undertreated clinical condition with special focus on colorectal cancer | Published in Clinical Hematology International the official peer-reviewed journal of @TheIACH chi.scholasticahq.com/articl…
Nicolas Stocker retweeted
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study | Blood | American Society of Hematology ashpublications.org/blood/ar…
Nicolas Stocker retweeted
Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Read the special report here: ow.ly/9MhZ50ZxFOe #ALL #SpecialReport #BloodJournal
Nicolas Stocker retweeted
#Myeloma Paper of the Day: 3-year follow-up of phase 1/2 MonumenTAL-1 shows talquetamab median PFS 7.5-11.2 mos, OS 28.3-not reached mos depending on cohort (less if prior CAR T/bsAb) w/ lower risk of high-grade infections vs. BCMA-targeting TCEs: pubmed.ncbi.nlm.nih.gov/4256…. #mmsm
Nicolas Stocker retweeted
"AI psychosis" is making headlines. But what does the evidence actually say?
Niall Boyce & Miriam Sabin are joined by psychiatrist Matthew Nour (University of Oxford & Microsoft AI) to separate fact from fiction on how AI might affect human mental health. 🎧 Listen: spkl.io/60197M161
Nicolas Stocker retweeted
The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma mdpi.com/4018024 #mdpicancers via @Cancers_MDPI #lymsm
Nicolas Stocker retweeted
Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group
thelancet.com/journals/lanha…
Nicolas Stocker retweeted
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
Read the full article. bit.ly/44YjXOM
Our latest IACH Post Congress Webinar:
𝗖𝗟𝗟 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗘𝗛𝗔
with Nicolas Stocker
Now available on demand
Watch the full webinar for FREE⬇️
iach.org/post-congress-webin…
@NStockerSAT @Mohty_EBMT
Nicolas Stocker retweeted
CONGRESS | #EHA2026 | PRESENTATION
Saad Usmani presents the final results from the phase III CEPHEUS study evaluating daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) vs VRd in TI-NDMM.
After a median follow-up of 76 months, D-VRd was associated with higher rates of MRD negativity than VRd, including 61.1% vs 40.0% at 10⁻⁵ (OR, 2,35; p = 0.0004) and 46.5% vs 27.6% at 10⁻⁶ (OR, 2.27; p = 0.001). D-VRd also reduced the risk of progression or death by 45% versus VRd (HR, 0.55; p = 0.0007). No additional safety concerns were identified with longer follow-up.
Follow our live feed for more updates: loom.ly/CXccZxs
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#MultipleMyeloma #myeloma #mmsm #MedEd
Nicolas Stocker retweeted
CONGRESS | #EHA2026 | PRESENTATION
Bertram Glass shares results from the final analysis of a phase III trial of Pola-R-ICE vs R-ICE as a 2L treatment for R/R LBCL (n = 294).
Pola-R-ICE did not significantly improve EFS vs R-ICE overall. Subgroup analysis suggested a PFS and OS benefit with Pola-R-ICE in patients with histologic subtype DLBCL, relapsed disease, and high tumor burden.
Follow our live feed for more updates: bit.ly/4akOvNA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @BuchHelios
Nicolas Stocker retweeted
CONGRESS | #EHA2026 | PRESENTATION
Eugen Tausch presents the final 5-year biomarker analysis of the phase III GAIA/CLL13 trial evaluating genetic predictors of efficacy with venetoclax-based regimens — rituximab + venetoclax (RV), obinutuzumab + venetoclax (GV), and obinutuzumab + ibrutinib + venetoclax (GIV) — vs chemoimmunotherapy (CIT) in fit patients with previously untreated CLL (N = 913).
At a median FU of 63.8 months, U-IGHV was independently prognostic for PFS with both venetoclax-based regimens (HR, 2.01; p < 0.001) and CIT (HR, 3.55; p < 0.001). With venetoclax-based regimens, complex karyotype (HR, 1.93; p < 0.001), mutated NOTCH1 (HR, 1.56; p = 0.003), and mutated EGR2 (HR, 1.61; p = 0.036) also remained independent adverse prognostic factors for PFS. For CIT, complex karyotype also remained independently prognostic for PFS (HR, 1.69; p = 0.019). At relapse, acquired resistance mutations were rare, with BCL2 mutations in 1.2% after RV and no acquired BTK/PLCG2 mutations; TP53 mutation/del(17p) evolution occurred less frequently after venetoclax-based therapy vs CIT.
Follow our live feed for more updates: loom.ly/ilKkUIM
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @uni_ulm
Nicolas Stocker retweeted
CONGRESS | #EHA2026 | POSTER
Albert Oriol shares findings from a post hoc analysis of the phase III IRAKLIA trial evaluating Isa + Pd by prior anti-CD38 exposure in patients with relapsed/refractory #MultipleMyeloma (N = 531; no prior anti-CD38, n = 464; prior anti-CD38, n = 67).
Patients with prior anti-CD38 exposure had a lower ORR vs those with no prior anti-CD38 exposure (52.2% vs 73.5%), alongside lower 12-month PFS (40.6% vs 68.8%; HR, 2.049; p = 0.0003). Among patients with prior anti-CD38 exposure, outcomes were similar by refractory status, with 12-month PFS of 42.2% vs 38.9% in refractory vs non-refractory patients (HR, 0.904; p = 0.7853). The safety profile of Isa + Pd was generally similar with vs without prior anti-CD38 exposure.
Follow our live feed for more updates: loom.ly/CXccZxs
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#myeloma #mmsm #MedicalCongress @ICO_oncologia @CarrerasIJC @hgermanstrias
